Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research report issued to clients and investors on Friday. They currently have a $33.00 target price on the stock. Wedbush’s price target suggests a potential upside of 98.08% from the company’s current price.

Several other analysts have also issued reports on VRNA. Zacks Investment Research upgraded shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Tuesday, July 25th. Jefferies Group LLC restated a “buy” rating and issued a $26.00 price target on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. SunTrust Banks, Inc. initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued a “buy” rating and a $26.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued a “buy” rating and a $22.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $24.20.

Verona Pharma PLC American Depositary Share (VRNA) opened at 16.66 on Friday. The company’s market cap is $184.33 million. Verona Pharma PLC American Depositary Share has a 12 month low of $11.03 and a 12 month high of $17.50. The stock’s 50 day moving average is $12.35 and its 200 day moving average is $13.57.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its earnings results on Tuesday, August 8th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.09. Equities analysts predict that Verona Pharma PLC American Depositary Share will post ($2.23) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Verona Pharma PLC American Depositary Share’s (VRNA) “Outperform” Rating Reiterated at Wedbush” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/08/verona-pharma-plc-american-depositary-shares-vrna-outperform-rating-reiterated-at-wedbush.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of VRNA. FIL Ltd acquired a new stake in Verona Pharma PLC American Depositary Share in the 2nd quarter worth $873,000. Tekla Capital Management LLC acquired a new stake in Verona Pharma PLC American Depositary Share in the 2nd quarter worth $3,211,000. Finally, Vivo Capital LLC acquired a new stake in Verona Pharma PLC American Depositary Share in the 2nd quarter worth $8,208,000. Institutional investors own 30.16% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.